Diffusion tractography uses the movement of water molecules to identify tracts that connect different parts of the brain. It can be used to pinpoint the part of the thalamus to treat with focused ultrasound. Image courtesy of UT Southwestern Medical Center

Diffusion tractography uses the movement of water molecules to identify tracts that connect different parts of the brain. It can be used to pinpoint the part of the thalamus to treat with focused ultrasound. Image courtesy of UT Southwestern Medical Center


June 15, 2020 — Recently developed magnetic resonance imaging (MRI) techniques used to more precisely target a small area in the brain linked to Parkinson's disease and essential tremor may lead to better outcomes without surgery and with less risk of negative effects, a new study led by UT Southwestern researchers suggests.

The study, published in Brain, describes recently refined MRI methods designed to allow neuroradiologists to zero in on a pea-sized region in the brain's thalamus involved in movement. Using the images, doctors then can use high-intensity focused ultrasound (HIFU) to ablate, or burn away, problem tissue, said Bhavya R. Shah, M.D., first author of the study and an assistant professor of radiology and neurological surgery at UT Southwestern's Peter O'Donnell Jr. Brain Institute.

"The benefit for patients is that we will be better able to target the brain structures that we want," Shah saidf. "And because we're not hitting the wrong target, we'll have fewer adverse effects." The procedures are already Food and Drug Administration-approved for use in patients, and UTSW plans to begin employing them to treat patients when its Neuro High Intensity Focused Ultrasound Program opens this fall.

Adverse effects from imprecise targeting include problems walking or slurring words. While such effects are usually temporary, they can be permanent in 15 to 20 percent of cases, said Shah.

According to the National Institutes of Health, essential tremor affects up to 10 million Americans and Parkinson's disease impacts more than 1 million. Both are neurologic diseases thought to have genetic links. The first line of treatment for the involuntary trembling or shaking seen with these diseases is medication. However, approximately 30 percent of patients do not respond well to drugs, according to the study.

In the late 1990s, neurosurgeons began using a procedure called deep brain stimulation, opening the skull to permanently implant metal electrodes that could then be stimulated via a battery pack.

About a decade ago, a new MRI-guided procedure emerged that uses high-intensity ultrasound waves to heat and eliminate a small section of the thalamus linked to the disorders. MRI-guided HIFU is currently approved for treatment of essential tremor and tremors seen in Parkinson's disease patients. The outpatient procedure does not require opening the skull, and the patient is awake while it is performed, said Shah. "No cuts. No anesthesia. No implanted devices."

A challenge in both procedures has been locating the precise area inside the brain's thalamus to treat - the pea-sized ventral intermediate nucleus, said Shah.

Traditionally, doctors have relied on either landmarks or maps of the brain drawn from cadavers to help them pinpoint the correct location. However, every brain is different, Shah said, and tiny errors can lead to damage in surrounding tissue, or to missing portions of the correct target.

Three newly refined MRI techniques are better at delineating the target tissue, according to the study.

The most widely studied and perhaps most promising imaging method is called diffusion tractography, said Shah. It creates precise brain images by taking into account the natural water movement within tissues.

The other methods described are quantitative susceptibility mapping - which creates contrast in the image by detecting distortions in the magnetic field caused by substances such as iron or blood — and fast gray matter acquisition TI inversion recovery — which operates much like a photo negative, turning the brain's white matter dark and its gray matter white in order to provide greater detail in the gray matter.

Shah and his team plan to participate in a multicenter clinical trial with collaborators at the Mayo Clinic in Rochester, Minnesota, testing the diffusion tractography method in patients.

For more information: www.swmed.edu


Related Content

News | Treatment Planning

May 6, 2024 — Elekta announced the acquisition of Philips Healthcare’s Pinnacle Treatment Planning System (TPS) patent ...

Time May 06, 2024
arrow
News | Magnetic Resonance Imaging (MRI)

May 6, 2024 — Hvidovre Hospital has the world's first prototype of a sensor capable of detecting errors in MRI scans ...

Time May 06, 2024
arrow
Feature | Digital Radiography (DR) | By Melinda Taschetta-Millane

Digital radiography (DR) continues to advance at a rapid pace with today’s technological innovations and evolving ...

Time May 06, 2024
arrow
Feature | Radiology Business | By Melinda Taschetta-Millane

One on One interviews with radiology trailblazers and historic FDA clearances made the top-read list for April. Take a ...

Time May 03, 2024
arrow
Feature | Radiation Dose Management | By Christine Book

Advances in the growing radiation dose management market are continually helping those who administer treatment to focus ...

Time May 03, 2024
arrow
News | Pediatric Imaging

May 2, 2024 — Head and abdominal trauma is a leading cause of death for children. About 1%–2% of children who come to ...

Time May 02, 2024
arrow
Feature | Radiology Business

Beginning this spring, ITN will begin sending out a bi-monthly survey to our readers on a variety of topics, which we ...

Time May 02, 2024
arrow
News | Breast Imaging

May 1, 2024 — After the issuance of updated breast screening recommendations by the U.S. Preventive Services Task Force ...

Time May 01, 2024
arrow
News | Ultrasound Imaging

April 30, 2024 — Best Nomos, a TeamBest Global Company, is launching its most modern, highly innovative Compact SONALIS ...

Time April 30, 2024
arrow
News | Proton Therapy

April 29, 2024 — Koneksa, a healthcare technology company pioneering evidence-based digital biomarkers, announced today ...

Time April 29, 2024
arrow
Subscribe Now